Physician profile
John Buchanan
NPI 1265001184
$8,143.38
in general payments reported to CMS, 2019-2025
38 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,797 · 2023: $3,369 · 2024: $1,638 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,390 · Travel and Lodging: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,389.64 |
| Travel and Lodging | $956.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,302.09 | 2022-2024 | Urolift |
| Axonics, INC. | $1,232.93 | 2022-2024 | Bulkamid, Axonics |
| Merck Sharp & Dohme LLC | $508.29 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $469.78 | 2022-2025 | |
| Coloplast Corp | $436.28 | 2022-2024 | Titan |
| Endo Pharmaceuticals INC. | $414.18 | 2022-2024 | Xiaflex, Aveed |
| Blue Earth Diagnostics | $403.56 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $311.48 | 2023-2024 | Orgovyx, Gemtesa |
| Pfizer INC. | $292.77 | 2022-2025 | |
| Boston Scientific Corporation | $267.10 | 2023-2025 | Ams 700, Lithovue, General - Erectile Dysfunction |
| Astrazeneca Pharmaceuticals Lp | $266.25 | 2022-2025 | Lynparza, Farxiga |
| Tolmar, INC. | $226.57 | 2023-2024 | |
| Myovant Sciences INC. | $196.08 | 2022 | |
| Dendreon Pharmaceuticals LLC | $186.47 | 2023-2024 | Provenge |
| Procept Biorobotics Corporation | $144.57 | 2022-2024 | Aquabeam Robotic System, Aquabeam System |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $132.21 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $130.67 | 2022 | |
| Amgen INC. | $119.37 | 2025 | Repatha |
| Abbvie INC. | $115.89 | 2023-2024 | |
| Abc Home Medical Supply, INC. | $101.52 | 2022-2024 | |
| Foundation Medicine, INC. | $99.24 | 2022-2023 | Foundationone Cdx, Foundationone Liquid Cdx |
| Janssen Biotech, INC. | $92.00 | 2022-2023 | Erleada |
| Ferring Pharmaceuticals INC. | $83.50 | 2024 | Adstiladrin |
| Antares Pharma, INC. | $81.33 | 2022-2024 | Xyosted |
| Olympus America INC. | $76.15 | 2022-2024 | Itind System |
| Astellas Pharma US INC | $69.79 | 2022-2023 | Xtandi |
| Angiodynamics, INC. | $64.15 | 2023-2024 | Nanoknife |
| Urovant Sciences INC | $58.46 | 2022 | |
| Acerus Pharmaceuticals Corporation | $44.94 | 2022 | |
| Endo USA, INC. | $42.11 | 2024 | Xiaflex |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.48 | 2025 | Lifevest |
| Verity Pharmaceuticals INC. | $24.69 | 2024 | Trelstar |
| Novo Nordisk INC | $23.09 | 2025 | Ozempic, Rybelsus |
| Civco Medical Instruments | $19.62 | 2023 | |
| Myriad Genetic Laboratories, INC. | $18.03 | 2023 | Prolaris |
| Progenics Pharmaceuticals, INC. | $17.95 | 2023 | Pylarify |
| Kowa Pharmaceuticals America, INC. | $17.70 | 2022 | |
| Baxter Healthcare | $17.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.